Clinical Trials Browser

Phase 3 × OTHER × exemestane × Clear all

NCT06671912 2026-06-02

LoTam

Phase 3 Suspended

Breast Carcinoma In Situ

NCT06507618 2026-05-08

POWER II

Phase 3 Recruiting

Breast Neoplasms

NCT02918084 2026-05-06

GIM10-CONSENT

Phase 3 Active not recruiting

Breast Neoplasms

NCT04852887 2026-04-23

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT00893061 2026-03-17

MNEMOSYNE

Phase 3 Completed

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

Phase 3 Active not recruiting

Breast Cancer Female

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

Breast Neoplasms

NCT07190443 2025-09-29

AURA

Phase 3 Recruiting

Breast Neoplasms

NCT04134598 2025-08-29

EUROPA

Phase 3 Active not recruiting

Breast Neoplasms

NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Phase 3 Not yet recruiting

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 3 Completed

622 enrolled 18 charts

Breast Neoplasms

NCT06223698 2025-04-20

SWE-Switch

Phase 3 Not yet recruiting

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04460807 2024-02-12

EXPERT

Phase 3 Terminated

Ovarian Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase 3 Terminated

First Line Metastatic Breast Cancer

NCT02511639 2020-12-03

MAIN-A

Phase 3 Completed

Breast Cancer Metastatic

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

Breast Neoplasms

NCT03137368 2018-10-31

STEP

Phase 3 Unknown

Breast Neoplasms

NCT01638247 2018-09-19

MALE

Phase 3 Completed

Breast Neoplasms, Male

NCT02404051 2016-06-15

FEVEX

Phase 3 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT00525096 2011-06-30

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

Phase 3 Unknown

Breast Neoplasms

NCT00810706 2008-12-18

ATENA

Phase 3 Terminated

Breast Neoplasms